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Abstract
Background—Low levels of brain-derived neurotrophic factor (BDNF) are linked to delayed 
neurological recovery, depression, and cognitive impairment following stroke. Supplementation 
with BDNF reverses these effects. Unfortunately, systemically administered BDNF in its native 
form has minimal therapeutic value due to its poor blood brain barrier permeability and short 
serum half-life. In this study, a novel nano-particle polyion complex formulation of BDNF (nano-
BDNF) was administered to mice after experimental ischemic stroke.
Methods—Male C57BL/6J (8–10 weeks) mice were randomly assigned to receive nano-BDNF, 
native-BDNF, or saline treatment after being subjected to 60 minutes of reversible middle cerebral 
artery occlusion (MCAo). Mice received the first dose at 3 (early treatment), 6 (intermediate 
treatment), or 12 hours (delayed treatment) following stroke onset; a second dose was given in all 
cohorts at 24 hours after stroke onset. Post-stroke outcome was evaluated by behavioral, 
histological, and molecular analysis for 15 days after stroke.
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Results—Early and intermediate nano-BDNF treatment led to a significant reduction in cerebral 
tissue loss. Delayed treatment led to improved memory/cognition, reduced post-stroke depressive 
phenotypes, and maintained myelin basic protein and brain BDNF levels, but had no effect on 
tissue atrophy.
Conclusions—The results indicate that administration of a novel nano-particle formulation of 
BDNF leads to both neuroprotective and neuro-restorative effects after stroke.
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INTRODUCTION
Stroke is the fifth leading cause of death in the United States and is a leading cause of adult 
disability (Mozaffarian et al., 2016). The long lasting impairments seen after stroke diminish 
independence and reduce quality of life in stroke survivors (Synhaeve et al., 2015). In 
addition to physical disability and cognitive impairments, post stroke depression (PSD) is 
also a frequent and important neuropsychiatric consequence of stroke (Lokk and Delbari, 
2010). About 40% of stroke survivors suffer from PSD (Lenzi et al., 2008). PSD develops 
soon after stroke, and can persist for years and impair neurological recovery after stroke 
(Zavoreo et al., 2009).
Given that stroke significantly impairs quality of life, it is imperative to find treatments that 
improve functional recovery after stroke onset. Brain derived neurotrophic factor (BDNF) 
induces neuronal plasticity and plays an important role in post stroke rehabilitation and 
recovery (Mang et al., 2013). Moreover, exogenous supplementation or overexpression of 
BDNF can reduce infarct volume, improve neurological outcome, enhance sensorimotor 
function and mediates both oligodendrogenesis and remyelination after white matter injury 
in experimental stroke models (Lee et al., 2010; Ramos-Cejudo et al., 2015; Schabitz et al., 
2007; Yasuhara et al., 2008).
Several laboratories, including ours, have shown that neuronal expression of BDNF 
increases acutely after stroke as a pro-survival response and that BDNF levels correlate with 
the degree of functional survival (Bejot et al., 2011; O'Keefe et al., 2014). Decreased or low 
BDNF levels have been associated with depression and cognitive impairment (Zhang et al., 
2012). Given the fact that BDNF has both neuroprotective and antidepressant/neuro-
restorative effects (Allen et al., 2015), BDNF may be a useful treatment strategy for acute 
stroke and post-stroke functional deficits. Despite the known benefits of BDNF, its 
usefulness in treating stroke, depression, and other neurological disorders is limited due to 
its poor accumulation by brain and short serum half-life (Pan et al., 1998). Although stroke 
disrupts the BBB and increases vascular permeability, this does not occur until several hours 
after stroke onset (Fluri et al., 2015; Hong et al., 2015). Furthermore, the BBB leakages that 
occur with stroke are often not of such a magnitude to allow large proteins, such as BDNF, 
to achieve substantial pharmacological levels within the brain (Sullivan et al., 2011).
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In order to have therapeutic value, these obstacles must be overcome either by conjugating 
BDNF to a BBB drug delivery system or by optimizing the pharmacokinetics of BDNF to 
increase plasma half-life. In this study, we utilized a polymeric nano-formulation of BDNF 
in which BDNF molecules were incorporated into polyion complexes with block 
copolymers composed of safe and biocompatible diblock copolymers of (poly(ethylene 
glycol) (PEG) and poly(L-glutamate) (PGA) to increase CNS delivery. We have previously 
validated similar technology for the CNS delivery of an active antioxidant enzyme (Jiang et 
al., 2015). The PEG-PGA block copolymers used in this nanoparticle formulation has been 
used in preclinical and clinical trials to treat cancer, among other diseases ((Danson et al., 
2004; Sahay et al., 2010; Valle et al., 2011). This delivery system is therefore very clinically 
relevant and could be used in stroke patients to improve functional recovery. In this work, 
the effectiveness of this novel nano-formulation of BDNF was examined. Both 
neuroprotective and neuro-restorative potential (an improvement in behavioral outcome 
without a change in infarct size) were examined after experimental stroke in mice.
METHODS
All animal protocols were approved by the Institutional Animal Care and Use Committee at 
the University of Connecticut Health Center and were performed in accordance with 
National Institutes of Health guidelines. C57Bl/6 male mice (8–10 weeks; 20–25g) were 
purchased from Jackson Laboratories (Bar Harbor, ME). After arrival, mice were 
acclimatized in the animal care facility for at least 2 weeks and were maintained in an 
ambient temperature and humidity controlled vivarium with free access to food and water ad 
libitum. After gross behavioral examination all mice underwent 60 minutes of MCAo and 
were randomly assigned to one of three treatment conditions and one of three treatment time 
groups. Mice in Group A (early treatment) were treated twice with BDNF nano-particles 
(nano-BDNF) (250µg/kg i.v; n=6/group) or saline at 3 and 24 hours after MCAo using 
lateral tail vein. Mice in Groups B (intermediate treatment) and C (delayed treatment) were 
treated with saline, nano-BDNF, or native-BDNF (250µg/kg i.v., n=4–8/group) at 6 and 24 
hours or 12 and 24 hours after MCAo, respectively. The amount of 250 µg/kg in our dose 
refers to the pure BDNF protein in the nanoformulation.
Additionally, a sub-cohort of mice in the delayed treatment group (Group D) underwent two 
additional behavioral tests, a memory test (Novel Objection Recognition Test) on days 7 and 
14 and a depression assessment (Tail Suspension Test) on day 14. All mice were sacrificed 
on day 15. Brains were used for cresyl violet staining, western blot analysis, or ELISA. 
Neurological deficit scores were recorded on days 0, 1, 3, 7, and 14. Serum samples were 
also collected at sacrifice and used for ELISA (See Figure 1). STAIR and RIGOR guidelines 
were followed in this study (Lapchak et al., 2013).
Stroke model
Focal transient cerebral ischemia was induced by a 60-minute right middle cerebral artery 
occlusion (MCAo) under Isoflurane anesthesia followed by reperfusion and 15 day survival 
as described previously (Verma et al., 2014). Briefly, a midline ventral neck incision was 
made and unilateral right MCAo was performed by advancing a 6.0 silicone rubber-coated 
Harris et al. Page 3
Pharmacol Biochem Behav. Author manuscript; available in PMC 2017 November 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
monofilament (Doccol Corporation, CA) 10–11 mm from the internal carotid artery 
bifurcation via an external carotid artery stump. Rectal temperatures were monitored with a 
temperature control system (Fine science tools, Canada) and were maintained at ~37 °C 
during surgery with an automatic heating pad. Laser Doppler Flowmetry (DRT 4/Moor 
Instruments Ltd, Devon, UK) was used to measure cerebral blood flow, and to confirm 
occlusion (reduction to 15% of baseline cerebral blood flow) and reperfusion. All animals 
were fed with wet mash for 1 week after surgery to ensure adequate nutrition for chronic 
endpoints, as animals have rearing deficits after stroke. Additionally, a daily subcutaneous 
injection of normal saline (volume=1% v/w) was given to all animals for 1 week.
Cresyl violet staining for Tissue Atrophy
Animals in groups A, B, and C were sacrificed 15 days after stroke surgery with an overdose 
of Avertin (250 mg/kg i.p). After blood collection by cardiac puncture, mice underwent 
trans-cardiac perfusion using cold PBS followed by 4% paraformaldehyde. Brains were then 
fixed overnight and placed in cyroprotectant (30% sucrose in PBS) for 72 hours before 
processing. Brains were then cut into 30-µm free-floating sections using a freezing 
microtome and every eighth slice was mounted and stained with cresyl violet. These 30-µm 
sections were then used for tissue atrophy calculation. Loss of brain tissue was determined 
by measuring the amount of tissue atrophy in the ipsilateral hemisphere. Tissue atrophy was 
calculated using the following formula: % tissue atrophy = (Total ipsilateral tissue/total 
contralateral tissue) × 100 (Verma et al., 2014). Data analysis was performed by an 
investigator blinded to the experimental cohort.
Western blot Analysis
Animals in group D were sacrificed 15 days after stroke surgery with an overdose of Avertin 
(250 mg/kg i.p) and blood was collected from the right ventricle. Mice underwent cervical 
dislocation followed by the rapid removal of the brain. The frontal cortical region of the 
right (ischemic) hemisphere was separated and homogenized as described previously (22). 
Protein concentration was determined using a BCA Protein Assay Kit (Thermo Fisher 
Scientific Inc., Rockford, IL) and subjected to Western Blotting as previously described 
(22). A total of 20 µg of protein was loaded into each well. Protein samples were resolved on 
4% to 15% SDS electrophoresis gels and transferred to a PVDF (polyvinylidene difluoride 
membrane). We examined the differences in expression patterns of myelin basic protein 
(MBP) (1:1000 Abcam), TrkB (1:1000 Santa Cruz) and actin (1:500, Sigma) in mice treated 
with nano-BDNF, native-BDNF, and saline. Densitometry of Western blotting images (n= 5/
group) was performed with computer software (Image J).
ELISA
Blood samples (Group D – see collection method above) were spun at 10,000g for 10 
minutes at 4*C; serum supernatant was collected. Both serum (no dilution factor; n=3–6/
group) and homogenized brain tissue (dilution factor: 1:2; n=3/group) were analyzed for 
BDNF levels using a BDNF (Mouse) ELISA Kit (Abnova).
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Neurological deficit
The neurological deficit score (NDS) is a crude assessment of post-stroke behavioural 
recovery. ND scores, ranging from 0 to 4, were recorded on days 0, 1, 3, 7, and 14 post-
MCAo (Liu et al., 2009). Our standard scoring system was as follows: 0, no deficit; 1, 
forelimb weakness and torso turning to the ipsilateral side when held by tail; 2, circling to 
affected side; 3, unable to bear weight on affected side; and 4, no spontaneous locomotor 
activity or barrel rolling (Venna et al., 2014).
Novel Object Recognition Task (NORT)
The NORT is used to evaluate cognition, particularly recognition memory, in rodent models 
of CNS disorders (Antunes and Biala, 2012). This test is based on the tendency of mice to 
spend more time exploring a novel object than a familiar one. This preference is used to 
assess intact recognition memory. Mice were placed in the behavioral room for an hour prior 
to testing to allow acclimatization. During habituation animals were allowed to explore an 
empty arena for at least 10 minutes. Twenty-four hours after habituation, animals were 
exposed to the familiar arena with 2 identical objects placed at an equal distance for 10 
minutes (trial phase). If the total time of exploration of these objects was greater than 20 
seconds, these mice qualified for the experimental test (Leger and Massoud, 2013) which 
was conducted 2 hours after the trial. One of the objects from the trial was replaced with a 
novel object. Mice were then allowed to explore the test arena for 10 minutes. The 
experiment was recorded using a digital video camera (JVC Everio, Victor Company, Japan) 
by a trained observer. A discrimination index (DI) was calculated by using the formula DI = 
(TN − TF)/(TN + TF), where TN= time spent exploring the novel object and TF= time spent 
in exploring of familiar objects. The NORT was performed on days 7 and 14 after stroke and 
analyzed by an experimenter blinded to treatment. Different novel objects were used each 
week; the arena was cleaned between tests to remove olfactory cues.
Tail Suspension test (TST)
The tail suspension test (TST) was performed as described previously (Chatterjee et al., 
2012) with minor modifications. Mice were placed in the behavioral room for an hour prior 
to testing to allow acclimatization. Briefly, the mice were individually suspended from the 
tail suspension apparatus, 60 cm above the surface of the table. The experiment was 
recorded for six minutes using a digital video camera (JVC Everio, Victor Company, Japan). 
A trained observer who was blinded to the treatment conditions then recorded the duration 
of immobility. The mouse was considered immobile in the absence of initiated movement. In 
general, an immobile mouse will appear to hang passively unless it has retained momentum 
from a movement immediately prior to the current bout of immobility. The testing apparatus 
was cleaned between trials to remove olfactory cues. Due to the potential stress induced by 
the TST, this was only performed once, on day 14, the day prior to sacrifice.
Statistics
All data were analyzed and expressed as means ± S. E. M. The non-parametric NDS in the 
3-hour cohort was analyzed via Mann-Whitney U test. Tissue atrophy in the 3-hour cohort 
was analyzed by a T test. Tissue atrophy for the 6 and 12-hour cohort, as well as NORT, 
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TST, western blot, and ELISA data, were analyzed by a one-way ANOVA with a Newman-
Keuls post hoc test to correct for multiple comparisons. A probability value of p< 0.05 was 
considered to be statistically significant.
Nano-BDNF
We prepared the nano-BDNF formulation by polyion complexation of human recombinant 
BDNF (Peprotech, Rocky Hill, NJ) with PEG(5 kDa)-PGA(9 kDa) diblock copolymer 
(Alamanda Polymers, Huntsville, AL) in aqueous solution in phosphate buffered saline, pH 
7.4 (Fig. 2). Dynamic light scattering (DLS) revealed that the complex particle size is 95 nm 
with a relatively small polydispersity index (PDI) of 0.165 (measured at 0.1 mg/mL BDNF 
in de-ionized water). This reaction between charged proteins with doubly hydrophilic block 
copolymers with ionic and nonionic blocks has been well characterized (Harada and 
Kataoka, 1998, 1999) and applied as protein delivery tools (Jiang et al., 2016; Jiang et al., 
2015; Manickam et al., 2012). The formulation was stored in the solution form at 4 °C 
before injection. The particle size did not change over the observation period of several 
weeks.
Radioactive Labeling of BDNF
BDNF and bovine serum albumin (BSA) were labeled with iodine by chloramine-T method 
(Yi et al., 2014). Briefly, BDNF was mixed with 1 mCi of Na125I or Na131I (Perkin Elmer) 
and 10 µg of chloramine-T in phosphate buffer (0.25 M, pH 7.5) for 60 s. Labeled protein 
was purified by Illustra Nap-5 columns (Life technologies) and collected in tubes pretreated 
with 1% BSA in PBS to prevent nonspecific adsorption. The iodine association (iodine in 
labeled sample/total iodine) was determined by trichloroacetic acid precipitation method (Yi 
et al., 2014). Briefly, 1 µl of purified samples was mixed with 0.5 ml of 1% BSA in PBS and 
0.5 ml of 30% trichloroacetic acid, and then centrifuged at 5400 g for 10 min. The resulted 
pellet and supernatant were counted on r-counter (PerkinElmer). The iodine association was 
calculated as the percentage of pellet radioactivity to total radioactivity. The iodine 
association for BSA/BDNF was higher than 85% and 98%, respectively. The 125I-labeled 
BDNF was used for preparation of polyion complexes with PEG-PGA (125I-labeled nano-
BDNF). In this case the tubes for preparation of the complexes were pre-coated with PEG-
PGA avoid the tracer adsorption on the walls.
Pharmacokinetics studies
The studies of pharmacokinetics of the BDNF and nano-BDNF were carried out in CD-1 
male mice (8 to 10 weeks of age) (Charles River Laboratories, Wilmington, Mass) as 
described previously (Yi et al., 2014). Briefly mice were be anesthetized with urethane and 
then given an injection into the tail vein of 125I-BDNF or 125I-nano-BDNF (3×105 cpm/
mouse) in 0.2 ml of saline; the injection also contained 131I-labeled BSA (3×105 cpm/
mouse) that served a measure the brain’s vascular space. The blood and whole brain were 
collected at different time points and measured in a gamma counter (3 mice per time point). 
As 131I and 125I are distinguishable in our gamma counter, we can measure cytokine and 
albumin uptake in the same animal. The volume of distribution (Vd), the serum half-life 
(t1/2), the brain/serum ratio (µL/g), the % of the injected dose in a ml of serum (%Inj/ml) and 
taken up per g of brain (%Inj/g), the Area Under the Curve (AUC) in serum and brain, and 
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the unidirectional influx rate (Ki, [µl/g-min]) were determined by multiple-time regression 
(Blasberg et al., 1983; Patlak et al., 1983).
RESULTS
BDNF nano-particles reduce tissue atrophy and improve neurological deficit scores
In our first experiment, we examined the neuroprotective potential of nano-BDNF. Mice 
were treated with nano-BDNF or saline at 3 and 24 hours after MCAo (Group A). We found 
a significant reduction in the amount of tissue lost (31.02±4.89% vs. 41.33+2.26%; 
p=0.0062) after nano-BDNF treatment (Fig. 2B). Moreover, nano-BDNF treated mice also 
showed earlier recovery of their neurological deficits on day 3 (Fig.3C and 3D).
Next, the therapeutic window of nano-BDNF was assessed. We also performed a direct 
comparison between nano-BDNF and native-BDN formulations. The first treatment dose 
(nano-BDNF, native-BDNF, or saline) was delayed until 6 hours after ischemic onset (Group 
B). Nano-BDNF significantly reduced tissue loss after MCAo compared to native-BDNF 
treatment (11.89+12.82% vs. 36.40+5.97%) [F (2, 12) = 8.256, p = 0.00432]; no difference 
in tissue loss was seen between saline and native-BDNF treatment (Fig. 4A). Similar to 3 
hour treatment, 6 hour treatment with nano-BDNF showed a positive trend in NDS. 
However, results were not significant (P= 0.13, 0.17 and 0.2302 at Day 3, 7 and 14 
respectively between saline and nano BDNF cohort B). In a third cohort (Group C and D), 
the first dose of nano-BDNF was further delayed until 12 hours after ischemic onset. In third 
cohort, however, no significant differences in tissue atrophy (Fig 4B) or NDS was found 
(Day 7: 1.43±.23 vs 1.16±0.3 vs 0.85±0.41 and day 14: 1.21± 0.25 vs 1±0.32 vs 0.8±0.43 
respectively in saline vs native vs nano-BDNF).
Delayed treatment with Nano-BDNF formulation improves memory and depressive 
behavior
BDNF treatment has been found to improve memory after stroke and have general 
antidepressant effects (Schmidt et al., 2011; Sirianni et al., 2010; Zhang et al., 2012). Given 
that we found no neuroprotective effects of nano-BDNF 12 hours after ischemia, we decided 
to evaluate an additional cohort of animals (Group D) for chronic behavioral changes after 
delayed BDNF treatment (treated at 12 and 24 hours post MCAo). This paradigm allows us 
to separate neuroprotective from neuro-restoration as infarct damage was equivalent in the 
treatment groups. Nano-BDNF treatment led to improved learning and memory at day 7 
after MCAo compared to saline treated mice (p<.05), as shown by a significantly higher 
discrimination Index (DI) [F (2, 12) = 4.224, p = 0.0468], while native-BDNF treatment led 
to intermediate effects (Fig. 5). It should be noted that nano-BDNF treated mice also had a 
higher DI at day 14, but this was not statistically significant, perhaps due to the repeated 
testing. In addition to an improvement in memory, delayed nano-BDNF treatment led to a 
reduction in depressive-like behavior as shown by significantly reduced immobility in the 
tail suspension test when compared to saline (p<.05) and native-BDNF treated mice (p<.01) 
[F (2, 12) = 9.953, p = 0.0034] (Fig. 6). These behavioral improvements were seen despite 
the lack of gross histological change.
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Nano BDNF treatment increases MBP expression and brain BDNF levels
The effect of nano-BDNF treatment on MBP and Trk-B expression in the frontal cortical 
region of right (ipsilateral) hemisphere was assessed in mice from the delayed treatment 
cohort (Group D). We found no significant difference in TrkB expression between groups 
(data not shown). We did, however, find that nano-BDNF treatment led to significantly 
increased expression of MBP compared to saline treatment (4.36+/− 0.20_vs. 2.56+/−0.08; p 
<.01); native-BDNF treatment led to a less significant increase in MBP levels when 
compared to saline treated animals (3.58+/−0.11 vs. 2.56+/−0.08); [F (2, 12) = 41.52, p = 
0.0065] (Fig. 7B). Mice treated with nano-BDNF had significantly higher brain BDNF 
levels than saline treated mice (1339.79+/−40.39 vs. 1145.08+/− 35.52) [F (2, 9) = 8.165, p 
= 0.0148] (Fig 8A), however, BDNF levels were not significantly different between native-
BDNF and saline treated mice. We found no differences in serum BDNF levels between 
groups (Fig. 8B).
To assess whether our nanoformulation increases the entry of the BDNF protein to the brain 
we characterized the pharmacokinetics of the free BDNF and nano-BDNF after IV 
administration. In this study, BDNF was labeled by I125 and then formulated with PEG-
PGA. These BDNF forms were administered IV into CD-1 mice and the radioactivity levels 
in the blood and brain, were measured at different time points (Fig. 9). The nano-BDNF 
shows similar serum clearance as BDNF (t1/2 15.6 min vs. 15.1 min). Importantly, the brain 
pharmacokinetics profile of nano-BDNF was drastically improved as demonstrated by: 1) 
increased influx rate across the blood brain barrier, measured by Ki at 0.84 µL/g.min (the 
slope); whereas BDNF was rapidly effluxed from brain to blood; 2) increased uptake 
compared to that of BDNF by over 6 times, calculated by AUC (2.96 (%inj/g) × (min) for 
nano-BDNF vs 0.54 for BDNF) over 10 min following IV injection; and 3) crossing the 
BBB and accumulation in brain parenchyma.
DISCUSSION
This study examined the neuroprotective and neuro-restorative efficacy of a novel nano-
BDNF formulation. Despite the fact that BDNF administration after stroke can reduce 
infarct size, limit post-stroke depressive behavior, enhances post-stroke sensorimotor 
recovery, cognition and neurogenesis in animal models, its limited brain bioavailability and 
short serum half-life have limited its usefulness in a clinical setting. In this study, we 
examined the efficacy of “nano-BDNF” in which BDNF molecules are incorporated into 
polyion complexes with block copolymers composed of safe and biocompatible polymers, 
poly (ethylene glycol) (PEG) and poly(L-glutamate) (PGA). We have previously validated 
the polyion complex technology in the delivery of an active antioxidant enzyme to the brain 
in an animal model of cerebral ischemia (Jiang et al., 2015). In this study, we evaluated 
nano-BDNF as a potential therapeutic agent for the treatment of brain injury in an animal 
model of stroke.
Although previous studies have shown the efficacy of BDNF in improving post-stroke 
recovery in animal models (Clarkson et al., 2015; Yu et al., 2013), BDNF was given quite 
quickly after stroke onset, a therapeutic time-window that is often not practical in clinical 
situations. In this study, extended therapeutic windows were evaluated, with treatment 
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delayed for over 12 hours after stroke onset. We first showed the efficacy of early nano-
BDNF treatment in reducing tissue loss. We next examined the efficacy of nano-BDNF at a 
later first dose time point, 6 hours. At this time point we also added a native-BDNF-
treatment as an additional control to rule out any contribution of the peripheral effects of 
BDNF treatment and to allow us to directly compare native BDNF with the novel nano-
BDNF formulation. We found that nano-BDNF treatment led to significantly reduced tissue 
damage when compared to native-BDNF, confirming the improved efficacy of the novel 
nanoparticle formulation.
We also examined the efficacy of nano-BDNF treatment at an even more delayed first dose 
time point, 12 hours after stroke onset. Delayed nano-BDNF treatment even as late as 12 
hours following stroke increased MBP expression and BDNF levels in the brain 15 days 
after drug administration. As the increased brain accumulation of BDNF after IV 
administration of nano-BDNF appears to be short-lived (minutes) we assume that any 
differences in brain BDNF levels at 15 days were due to differences in endogenous 
activation of BDNF, and not due to residual BDNF from the initial tail vein injection.
Moreover, 12 hour nano-BDNF also reduced post-stroke depressive phenotypes, and 
improved cognitive deficits. Many previous studies have found post-stroke behavioral 
improvement even in the absence of histological changes especially at chronic endpoints 
(Johansson, 1996; Johansson and Ohlsson, 1996; Yamamoto et al., 1989), which was seen in 
this study. Gain or loss of BDNF has been shown to lead to an increase or decrease in MBP 
expression respectively (Djalali et al., 2005). The upregulation of MBP and brain BDNF 
levels after nano-BDNF treatment supports the hypothesis that the behavioral recovery that 
we observed was due to nano-BDNF and this formulation is superior to that of native-
BDNF. Taken together, these results suggest that delayed treatment of nano-BDNF beyond 6 
hours is not neuroprotective, as infarct size was equivalent, however nano-BDNF continues 
to have important neuro-restorative effects that are seen weeks after drug administration. 
Targeting the recovery phase of stroke may lead to enhancement of functional outcomes that 
are independent of infarct size.
The benefits of BDNF treatment have been linked to enhancements in neurogenesis, brain 
repair, neuronal activity, cell survival as well as remyelination after white matter injury in 
subcortical stroke models (Hermann and Chopp, 2012; Murphy and Corbett, 2009). 
However, the exact mechanism by which BDNF is restorative is not well understood. Our 
observation that nano-BDNF treatment increases the expression of MBP even after delayed 
treatment is consistent with previous findings (Ramos-Cejudo et al., 2015). As enhancing 
MBP can have positive effects on both cognitive and motor skills (Lu et al., 2013; McKenzie 
et al., 2014), the increase in MBP expression may be partially responsible for the behavioral 
improvements seen in the cohorts of mice treated with nano-BDNF.
We do not report here on the mechanism of action of nano-BDNF as these studies were 
focused on determining the translational value of these novel nanoparticles as a therapy for 
stroke. We and others have previously shown that enhanced behavioral recovery in stroke 
mice is secondary to an enhancement in neurogenesis (Schabitz et al., 2007; Venna et al., 
2014). Specifically, one study has found that behavioral improvements after stroke paralleled 
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changes in BDNF levels and neurogenesis in the SVZ (Schabitz et al., 2007; Venna et al., 
2014). Additionally, increased neurogenesis has been found to lead to improvements in 
object recognition, spatial learning, and overall cognitive performance, and also reduces 
depressive-like behaviors (Hill et al., 2015; Sahay et al., 2011). In addition to enhancing 
neurogenesis and increasing MBP expression, BDNF also increases dendritic spine density 
and cAMP response element-binding (CREB) expression in astrocytes (Pilakka-Kanthikeel 
et al., 2013). Increases in both dendritic spine density and CREB expression enhance 
memory consolidation (Barco et al., 2003; Kasai et al., 2010). Moreover, the upregulation of 
CREB levels is associated with improvement of depressive behavior in rats (Itoh et al., 
2004). Therefore, BDNF’s effect on CREB expression, dendritic spine density, MBP 
expression, and/or neurogenesis, may all be potential mechanism through which our nano-
BDNF formulation led to improvements in learning/cognition and depressive phenotype in 
delayed treatment cohort. These will be examined in future studies now the efficacy of this 
treatment has been confirmed. Additional studies are needed to assess the effectiveness of 
delayed nano-BDNF in females and aged animals to move this agent into therapeutic trials.
SUMMARY/LIMITATIONS
The purpose of this study was to examine the efficacy of a novel nanoparticle formulation of 
BDNF in improving post-stroke recovery. Administration of nano-BDNF improved 
neuropathological and neurobehavioral outcomes after stroke. Early and intermediate 
treatment (3 and 6 hours) after stroke onset led to reduced tissue atrophy. Delayed (12 hour) 
treatment led to increased expression of MBP and improvements in memory and depressive 
phenotypes beyond that seen with native BDNF or saline treatment. Therefore, this nano-
formulation of BDNF has novel and additional benefits beyond that of BDNF, and has a 
wide therapeutic window. Despite the important findings with our BDNF nano formulation, 
there were several limitations in this initial study. First, we used a dose that was predicted 
based on in vitro studies, nano-BDNF pharmacokinetics studies in healthy animals and prior 
studies using exogenous non-nano BDNF formulations (250 µg/kg), which was found 
effective. Optimization of our dosing regimen and route are needed and pharmacokinetics 
studies of BDNF forms that would need to be carried out using the MCAo model. Second, 
we used relatively low numbers of animals in these studies, which were sufficient to show 
significant histological differences between groups (the primary outcome variable of the 
present study). In all of the infarct studies we perform in our laboratory, we undertake an 
interval analysis after 5–6 animals to refine the animal numbers needed to reach significance 
(or for futility) using power analysis (G*power). In this case, significance was seen with 
relatively small numbers, speaking to the potential of nano-BDNF to reduce injury. Our 
main aim for the study was to validate this nano-formulation for in vivo use. Our initial 
findings are very encouraging that this formulation of BDNF will have considerable 
potential to reduce stroke-induced tissue damage and its related disability. Moreover, we 
hypothesize that the small sample size may have accounted for the lack of significance in 
our intermediate and delayed treatment groups. We did not, however, increase the sample 
size given that we already found significant differences in tissue atrophy in this group. As 
NDS is known to be relatively insensitive after the first few days after stroke in young 
animals (Li et al., 2004), we therefore used more sensitive behavioral tests at longer time 
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points (e.g. TST and NORT), for which we found significant differences. A separately 
standing question relates to the mechanism of release of the active BDNF from the nano-
BDNF polyion complex which is a of an ongoing study that will be published elsewhere. 
Here we would like to point out that nano-BDNF is similar to the DNA/polycation 
complexes (“polyplexes”) that have been extensively studied. Such complexes are very 
stable but have a dynamic character and can undergo very rapid (seconds) cooperative 
reactions of polyion interchange resulting in displacement of one polyion by another which 
believed to be responsible for the release and subsequent processing of the DNA from 
polyplexes(Chelushkin et al., 2008; Kabanov and Kabanov, 1995) Clearly such processes are 
also responsible for the formation and subsequent transitions of nano-BDNF especially upon 
its interaction with the high affinity TrkB receptor. Future work will further develop this 
promising agent using animals with common co-morbidities (aged, hypertensive, etc.) and 
utilizing large animal models of stroke.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Highlights
1. Nano formulation of BDNF is both neuro-protective and neuro-
restorative.
2. Early treatment with nano-BDNF reduce infarct after stroke
3. Delayed treatment ameliorates depressive behavior and memory loss.
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Figure 1. 
Experimental design. Middle cerebral artery occlusion (MCAo) was performed on day 0 and 
either nano-BDNF, native-BDNF, or saline was injected intravenously at the respective time 
points. Brain tissue samples were collected from all mice on day 15 and were analyzed for 
tissue atrophy (in Groups A, B, and C) and for western blot analysis (in Group D). Tissue 
loss was calculated by subtracting the ischemic hemisphere (damaged) volume, including 
ipsilateral ventricle, from non-ischemic volume, including contralateral ventricle. A) Early 
treatment group: Neurological deficit scores were collected on days 0, 1, 3, 7 and 14. B) 
Intermediate treatment group. C) Delayed treatment group. D) Additional delayed treatment 
sub-cohort: Due to the lack of any difference in tissue atrophy outcome in our 12 hour group 
(Group C), we performed additional behavioral tests, and western blot and ELISA analysis 
in an additional 12 hour cohort (Group D).
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Figure 2. 
Schematic illustration showing the spontaneous formation of BDNF nano particle in water 
upon simple mixing of the native BDNF and PEG-PGA block copolymer. BDNF 
electrostatically couples with the oppositely charged PGA chain and entraps into a particle 
core surrounded by a shell of uncharged water-soluble PEG.
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Figure 3. 
A) Representative images of cresyl violet stained coronal brain sections. B) Group A: 
Quantification of tissue atrophy. Mice treated with nano-BDNF formulation (3 and 24 hours 
post MCAO) had significantly reduced tissue loss compared to saline treated mice on day 7 
of survival (p=0.0062; n=5/group). (C) Line graph showing the recovery trajectory of nano-
BDNF and saline treated mice; on day 3 mice treated with nano-BDNF formulation (3 and 
24 hours post MCAO) had significantly improved neurological deficit scores compared to 
saline on day 3 after MCAO. (D) Day 3 NDS. Bar graph.
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Figure 4. 
Groups B and C: Quantification of tissue atrophy. A) Mice treated with nano-BDNF 6 and 
24 hours post MCAo had significantly reduced tissue loss compared to saline treated mice 
after 15 days of survival ([F (2, 12) = 8.256, p = 0.00432; n=5/group). B) Delayed treatment 
with nano-BDNF (12 and 24 hours post MCAO) did not significantly reduce tissue loss 
compared to native-BDNF or saline treatment.
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Figure 5. 
Group C: Novel Object Recognition Test. Despite the lack of significant histological 
changes in infarct volume, nano-BDNF treated mice (12 and 24 hours post MCAO) had 
improved learning and memory on day 7, as shown by a significantly higher discrimination 
Index (DI), when compared to saline and native-BDNF treated mice ([F (2, 12) = 4.224, p = 
0.0468] (n=5group). BDNF treated mice also had a higher DI at day 14, but this was not 
significant.
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Figure 6. 
Group C: Tail Suspension Test. Despite the absence of changes in infarct volume, nano-
BDNF treated mice (12 and 24 hours post MCAO) had significantly reduced immobility 
compared to saline (p<.05) and native (p<.01) treated mice [F (2, 12) = 9.953, p = 0.0034] 
(n=5/group), signifying a reduced depressive phenotype.
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Figure 7. 
Group C: Western Blot analysis. A) Representative image. B) Nano treatment (12 and 24 
hours post MCAO) led to a more significant increase in MBP levels (p<.01) compared to 
saline than did native-BDNF treated mice [F (2, 12) = 41.52, p = 0.0065] (n=5/group). Two 
MBP specific bands were present between 17–22kDa.
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Figure 8. 
Brain and serum BDNF ELISA. A) Despite the lack of significant histological changes in 
infarct volume, nano-BDNF treated mice (12 and 24 hours post MCAO) had significantly 
higher brain BDNF levels than saline treated mice 15 days following MCAO ([F (2, 9) = 
8.165, p = 0.0148] (n=4/group); however, there were no significant differences between nano 
and native-BDNF treated mice or between saline and native-BDNF treated mice. B) There 
were no significant differences between groups in serum BDNF levels (n= 3–6/group).
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Figure 9. 
Brain pharmacokinetics study shows that (A) nano-BDNF clears from the circulation 
similarly to native BDNF; (B) nano-BDNF displays net influx (Ki = 0.84 uL/g.min) into the 
brain, whereas native BDNF displays a net efflux from brain to the blood; (C) consequently 
nano-BDNF displays higher brain uptake than native BDNF, as shown by AUC of 2.96 for 
nano-BDNF vs 0.54 for native BDNF. The native BDNF or nano-BDNF were injected IV at 
a single dose of 25 µg/kg. In Plot B, the slope and Y-intercept of the brain/serum ratio 
determine the Ki (influx rate) and Vi (initial volume of distribution) of the drug, respectively. 
The negative slope for the native BDNF (negative influx rate) means that there is efflux of 
native BDNF from the brain. In the case of nano-BDNF, the slope is positive suggesting that 
there is net influx. Since this is a single bolus injection experiment the ratio changes over 
time.
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